Form 4: Twist Bioscience Director Crandell Receives Equity Award

Twist Bioscience Corp Director Keith Crandell was granted 5,095 shares of common stock as an annual equity award, vesting in 2026.

Summary

• Keith Crandell, a Director of Twist Bioscience Corp (TWST), was granted 5,095 shares of common stock.
• The transaction date for this acquisition was February 5, 2026.
• The shares were acquired at a price of $0, indicating a grant rather than a purchase.
• Following this transaction, Crandell directly owns 27,571 shares and indirectly owns 76,047 shares through the Keith L. Crandell Trust.
• The 5,095 shares are part of an Annual Equity Award and will vest 100% upon the earlier of the one-year anniversary of the grant date or the date of the first annual meeting of stockholders following the grant date, provided Crandell remains a Service Provider.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, as it represents a standard practice of aligning director incentives with shareholder interests through equity compensation, without indicating any unusual or concerning activity.

Positives

• The grant of 5,095 shares to Director Keith Crandell aligns his interests with those of shareholders, incentivizing long-term company performance.
• Equity awards are a standard component of non-employee director compensation, reflecting good corporate governance practices.

Future Outlook

The shares granted to Director Crandell are scheduled to vest upon the earlier of the one-year anniversary of the grant date (February 5, 2027) or the date of the first annual meeting of stockholders following the grant date, contingent on his continued service.

Industry Context

StockSavvy.ai notes that equity compensation for non-employee directors, such as the grant to Keith Crandell, is a common practice across the biotechnology and life sciences sectors. This approach is designed to align the interests of directors with those of shareholders, fostering a long-term perspective on company performance and strategic decision-making. It is a standard mechanism for attracting and retaining experienced board members in competitive industries.

Comparison to Industry Standards

• The grant of equity as compensation for non-employee directors is a widely accepted practice, comparable to compensation structures at companies like Illumina (ILMN) or Danaher (DHR), which frequently use stock awards to incentivize their board members.
• The vesting schedule, tied to either a one-year anniversary or the next annual meeting, is typical for annual director grants, ensuring continued service and commitment.

Corporate Governance

Related Party Transactions

• The grant of 5,095 shares of common stock to Keith Crandell, a Director of Twist Bioscience Corp, constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with those of shareholders, potentially leading to decisions that enhance long-term shareholder value.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• The 5,095 shares granted to Keith Crandell will vest 100% upon the earlier of February 5, 2027 (one-year anniversary of grant) or the date of the first annual meeting of stockholders following the grant date.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to a non-employee director, which is a standard component of compensation and aligns director interests with shareholders. It does not present new information that would fundamentally alter the investment thesis for Twist Bioscience, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Twist Bioscience, TWST, Keith Crandell, Director, Equity Award, Stock Grant, Insider Transaction, Form 4, Beneficial Ownership, Corporate Governance